on Lir Life Sciences Corp. (CVE:SKNY)
LIR Life Sciences Initiates Phase 1 Transdermal Delivery Development
LIR Life Sciences Corp. announced the start of Phase 1 for its macromolecule-enabled transdermal delivery system with Neuland Laboratories. Neuland, responsible for chemical synthesis, will produce 200 mg of a transdermal agent, focusing on synthesis, purification, and characterization. This marks the initial step in a development program supporting formulation, transdermal testing, and future evaluation with LIR's research partners.
This collaboration aims to refine needle-free, skin-applied delivery methods for peptide-based therapies, supplementing LIR's broader preclinical efforts. The generated data will guide optimization and lead candidate selection for further progress. Edward Mills, CEO, highlighted the significance of this phase in enhancing formulation and transdermal performance understanding.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Lir Life Sciences Corp. news